Harvard Bioscience (HBIO) Amortization of Deferred Charges (2010 - 2026)
Harvard Bioscience (HBIO) reported Amortization of Deferred Charges of $446000.0 for Q1 2026, up 240.46% year-over-year from $131000.0 in Q1 2025, and down 28.53% quarter-over-quarter from $624000.0 in Q4 2025.
Harvard Bioscience (HBIO) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Amortization of Deferred Charges data on file, last reported at $446000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $446000.0, up 240.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 321.91% YoY), and the FY2025 annual result was $1.3 million, up 304.28% from the prior year.
- Amortization of Deferred Charges slipped to $446000.0 in Q1 2026 per HBIO's latest filing, from $624000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $624000.0 in Q4 2025 and troughed at $70000.0 in Q1 2022.
- A 5-year average of $156176.5 and a median of $70000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2025: Amortization of Deferred Charges changed 0.0% in 2022, then jumped 536.73% in 2025.
- A 5-year view of Amortization of Deferred Charges shows it stood at $70000.0 in 2022, then changed by 0.0% to $70000.0 in 2023, then soared by 40.0% to $98000.0 in 2024, then jumped by 536.73% to $624000.0 in 2025, then decreased by 28.53% to $446000.0 in 2026.
- Business Quant data shows HBIO's Amortization of Deferred Charges at $446000.0 in Q1 2026, $624000.0 in Q4 2025, and $357000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 446,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 624,000.00 |
| Dec 31, 2025 | 624,000.00 |
| Sep 30, 2025 | 357,000.00 |
| Sep 30, 2025 | 357,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |